| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Division of Differentiation and Carcinogenesis,* German Cancer Research Center, Heidelberg, Germany; the Department of Ophthalmology, University of Heidelberg Hospitals and Clinics, Heidelberg, Germany; the Department of Ophthalmology, University of Bonn, Bonn, Germany; and ImClone Systems Incorporated, New York, New York
Vascular endothelial growth factor (VEGF) plays a key role in tumor angiogenesis, and blockade of VEGF receptor 2 (VEGFR-2), with the monoclonal antibody DC101, inhibits angiogenesis and tumor growth. To examine the short-term effects of DC101, we surface transplanted the squamous cell carcinoma cell line A5-RT3 onto nude mice. After short-term treatment with DC101, we observed rapid reduction in vascularization and reversion of the tumor phenotype. Beginning 24 hours after treatment, VEGFR-2 inhibition resulted in decreased vessel density within the tenascin-c-staining tumor-associated stroma and reduced endothelial cell proliferation. Stromal expression of matrix metalloproteinase-9 and -13 was drastically reduced 96 hours after VEGFR-2 inhibition as detected by in situ hybridization and in situ zymography. Moreover, the morphology of the tumor-stroma border changed from a highly invasive carcinoma to a well-demarcated, premalignant phenotype. The latter was characterized by the appearance of a regular basement membrane in immunostaining and ultrastructural analyses. These findings suggest that VEGFR-2 inhibition by DC101 evokes very rapid reduction of preformed vessels and decreases both stromal protease expression and gelatinolytic activity, resulting in the modulation of the tumor-stroma border zone and reversion of the tumor phenotype. Thus, short-term inhibition of VEGF signaling results in complex stromal alterations with crucial consequences for the tumor phenotype.
This article has been cited by other articles:
 |
|
 |
|
  W. Lederle, N. Linde, J. Heusel, J. Bzyl, E. C. Woenne, S. Zwick, M. Skobe, F. Kiessling, N. E. Fusenig, and M. M. Mueller Platelet-Derived Growth Factor-B Normalizes Micromorphology and Vessel Function in Vascular Endothelial Growth Factor-A-Induced Squamous Cell Carcinomas Am. J. Pathol., February 1, 2010; 176(2): 981 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hadler-Olsen, P. Kanapathippillai, E. Berg, G. Svineng, J.-O. Winberg, and L. Uhlin-Hansen Gelatin In Situ Zymography on Fixed, Paraffin-embedded Tissue: Zinc and Ethanol Fixation Preserve Enzyme Activity J. Histochem. Cytochem., January 1, 2010; 58(1): 29 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Degen, F. Brellier, R. Kain, C. Ruiz, L. Terracciano, G. Orend, and R. Chiquet-Ehrismann Tenascin-W Is a Novel Marker for Activated Tumor Stroma in Low-grade Human Breast Cancer and Influences Cell Behavior Cancer Res., October 1, 2007; 67(19): 9169 - 9179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Smith, N. H. James, I. Oakley, A. Wainwright, C. Copley, J. Kendrew, L. M. Womersley, J. M. Jurgensmeier, S. R. Wedge, and S. T. Barry Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts Mol. Cancer Ther., August 1, 2007; 6(8): 2198 - 2208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Willhauck, N. Mirancea, S. Vosseler, A. Pavesio, P. Boukamp, M. M. Mueller, N. E. Fusenig, and H.-J. Stark Reversion of tumor phenotype in surface transplants of skin SCC cells by scaffold-induced stroma modulation Carcinogenesis, March 1, 2007; 28(3): 595 - 610. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
